Pharmacologic administration of interleukin-2.

Pharmacologic administration of interleukin-2.

Item
http://www.wikidata.org/entity/Q34092747
Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4.Autophagy is required for IL-2-mediated fibroblast growth.Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases.Effect of combined treatment with recombinant interleukin-2 and allicin on pancreatic cancer.Cell-mediated autophagy promotes cancer cell survival.Meeting report: The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Ohio; March 1-2, 2010.Regulatory T cells control toxicity in a humanized model of IL-2 therapy.Prospects of IL-2 in Cancer Immunotherapy.
P2860

Pharmacologic administration of interleukin-2.

Item
http://www.wikidata.org/entity/Q34092747
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pharmacologic administration of interleukin-2.
@ast
Pharmacologic administration of interleukin-2.
@en
Pharmacologic administration of interleukin-2.
@nl
type
label
Pharmacologic administration of interleukin-2.
@ast
Pharmacologic administration of interleukin-2.
@en
Pharmacologic administration of interleukin-2.
@nl
prefLabel
Pharmacologic administration of interleukin-2.
@ast
Pharmacologic administration of interleukin-2.
@en
Pharmacologic administration of interleukin-2.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P478
P50
P577
P698
P921
P356
P1433
P1476
Pharmacologic administration of interleukin-2
@en
P2093
P304
P31
P356
10.1111/J.1749-6632.2009.05160.X
P407
P478
P50
P577
P698
P921